3billion is looking to expand its global drug development partnerships as it prepares to present its AI-powered drug discovery platform and pipeline next week at BIO-Europe 2026 in Cologne, Germany. The company plans to meet with pharmaceutical and biotechnology organizations to explore joint research and development opportunities, including programs with potential for future licensing and commercialization.

Pavel Printsev, 3billion’s chief business development officer, will outline the company’s Genetics-First AI Drug Discovery strategy. The approach draws on genomic information from more than 120,000 patients, over 600,000 clinical case records and proprietary artificial intelligence models to identify potential therapeutic targets and design drug candidates.

A central element of the strategy is the study of genetic modifiers that affect disease onset and severity. By examining individuals who carry disease-associated genetic variants but remain asymptomatic or develop only mild symptoms, 3billion aims to identify protective biological mechanisms that could inform new therapeutic approaches. The company uses these findings to identify targets that may enable treatments to replicate naturally occurring protective effects.

Beyond genomic target discovery, 3billion applies its AI technologies to identify potential drug-binding sites on proteins that have historically been difficult to target. Its platform is also used to design small molecules capable of interacting with these sites.

The company is advancing oral small-molecule discovery programs in several therapeutic areas, including oncology and immunology. Its research covers multiple stages of early drug discovery, from target identification and hit discovery through lead identification and optimization.

During BIO-Europe, 3billion will also hold partnering discussions with global pharmaceutical and biotechnology companies. The company is seeking collaborators that can combine its patient genomic datasets, AI-based target identification and molecular design capabilities with complementary therapeutic knowledge and experimental validation resources.

Printsev says the company aims to translate insights from patient genomic data into drug discovery programs and sees the conference as an opportunity to identify partners with complementary expertise. The discussions are intended to establish potential joint research and development programs and advance assets toward future licensing and commercialization opportunities.

For more information, visit www.3billion.io.